Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(1):127–132. doi: 10.1038/sj.bjc.6690661

Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer

J S Keum 1, G Kong 2, S C Yang 3, D H Shin 3, S S Park 3, J H Lee 3, J D Lee 2
PMCID: PMC2374356  PMID: 10487623

Abstract

Cyclin D1 is one of the G1 cyclins that control cell cycle progression by allowing G1 to S transition. Overexpression of cyclin D1 has been postulated to play an important role in the development of human cancers. We have investigated the correlation between cyclin D1 overexpression and known clinicopathological factors and also its prognostic implication on resected non-small-cell lung cancer (NSCLC) patients. Formalin-fixed and paraffin-embedded tumour tissues resected from 69 NSCLC patients between stages I and IIIa were immunohistochemically examined to detect altered cyclin D1 expression. Twenty-four cases (34.8%) revealed positive immunoreactivity for cyclin D1. Cyclin D1 overexpression is significantly higher in patients with lymph node metastasis (50.0% vs 14.4%, P = 0.002) and with advanced pathological stages (I, 10%; II, 53.8%; IIIa, 41.7%, P = 0.048; stage I vs II, IIIa, P = 0.006). Twenty-four patients with cyclin D1-positive immunoreactivity revealed a significantly shorter overall survival than the patients with negativity (24.0 ± 3.9 months vs 50.1 ± 6.4 months, P = 0.0299). Among 33 patients between stages I and II, nine patients with cyclin D1-positive immunoreactivity had a much shorter overall survival (29.7 ± 6.1 months vs 74.6 ± 8.6 months, P = 0.0066). These results suggest that cyclin D1 overexpression is involved in tumorigenesis of NSCLCs from early stage and could be a predictive molecular marker for poor prognosis in resectable NSCLC patients, which may help us to choose proper therapeutic modalities after resection of the tumor. © 1999 Cancer Research Campaign

Keywords: non-small-cell lung cancer, cyclin D1, immunohistochemistry, progression, prognosis

Full Text

The Full Text of this article is available as a PDF (288.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akervall J. A., Michalides R. J., Mineta H., Balm A., Borg A., Dictor M. R., Jin Y., Loftus B., Mertens F., Wennerberg J. P. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer. 1997 Jan 15;79(2):380–389. [PubMed] [Google Scholar]
  2. Bartkova J., Lukas J., Strauss M., Bartek J. Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol. 1994 Mar;172(3):237–245. doi: 10.1002/path.1711720303. [DOI] [PubMed] [Google Scholar]
  3. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene. 1995 Feb 16;10(4):775–778. [PubMed] [Google Scholar]
  4. Betticher D. C., Heighway J., Hasleton P. S., Altermatt H. J., Ryder W. D., Cerny T., Thatcher N. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996 Feb;73(3):294–300. doi: 10.1038/bjc.1996.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Caputi M., De Luca L., Papaccio G., D'Aponte A., Cavallotti I., Scala P., Scarano F., Manna M., Gualdiero L., De Luca B. Prognostic role of cyclin D1 in non small cell lung cancer: an immunohistochemical analysis. Eur J Histochem. 1997;41(2):133–138. [PubMed] [Google Scholar]
  6. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C. A., Basolo F., Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995 May;71(5):1003–1007. doi: 10.1038/bjc.1995.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., Barnes D., Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994 Apr 1;54(7):1812–1817. [PubMed] [Google Scholar]
  8. Izbicki J. R., Passlick B., Hosch S. B., Kubuschock B., Schneider C., Busch C., Knoefel W. T., Thetter O., Pantel K. Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg. 1996 Sep;112(3):623–630. doi: 10.1016/S0022-5223(96)70044-2. [DOI] [PubMed] [Google Scholar]
  9. Jares P., Fernández P. L., Campo E., Nadal A., Bosch F., Aiza G., Nayach I., Traserra J., Cardesa A. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res. 1994 Sep 1;54(17):4813–4817. [PubMed] [Google Scholar]
  10. Jiang W., Kahn S. M., Tomita N., Zhang Y. J., Lu S. H., Weinstein I. B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res. 1992 May 15;52(10):2980–2983. [PubMed] [Google Scholar]
  11. Kayser K., Bülzebruck H., Probst G., Vogt-Moykopf I. Retrospective and prospective tumor staging evaluating prognostic factors in operated bronchus carcinoma patients. Cancer. 1987 Jan 15;59(2):355–361. doi: 10.1002/1097-0142(19870115)59:2<355::aid-cncr2820590232>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  12. Kern J. A., Slebos R. J., Top B., Rodenhuis S., Lager D., Robinson R. A., Weiner D., Schwartz D. A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest. 1994 Feb;93(2):516–520. doi: 10.1172/JCI117001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kwa H. B., Michalides R. J., Dijkman J. H., Mooi W. J. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer. 1996 Jun;14(2-3):207–217. doi: 10.1016/0169-5002(96)00547-8. [DOI] [PubMed] [Google Scholar]
  14. Lovec H., Sewing A., Lucibello F. C., Müller R., Möröy T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene. 1994 Jan;9(1):323–326. [PubMed] [Google Scholar]
  15. Lukas J., Pagano M., Staskova Z., Draetta G., Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene. 1994 Mar;9(3):707–718. [PubMed] [Google Scholar]
  16. Mate J. L., Ariza A., Aracil C., López D., Isamat M., Pérez-Piteira J., Navas-Palacios J. J. Cyclin D1 overexpression in non-small cell lung carcinoma: correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol. 1996 Dec;180(4):395–399. doi: 10.1002/(SICI)1096-9896(199612)180:4<395::AID-PATH688>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  17. McIntosh G. G., Anderson J. J., Milton I., Steward M., Parr A. H., Thomas M. D., Henry J. A., Angus B., Lennard T. W., Horne C. H. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995 Sep 7;11(5):885–891. [PubMed] [Google Scholar]
  18. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995 Mar 1;55(5):975–978. [PubMed] [Google Scholar]
  19. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst. 1993 Dec 15;85(24):2018–2023. doi: 10.1093/jnci/85.24.2018. [DOI] [PubMed] [Google Scholar]
  20. Mountain C. F., Lukeman J. M., Hammar S. P., Chamberlain D. W., Coulson W. F., Page D. L., Victor T. A., Weiland L. H. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol. 1987 Jul;35(3):147–156. doi: 10.1002/jso.2930350302. [DOI] [PubMed] [Google Scholar]
  21. Muller D., Millon R., Lidereau R., Engelmann A., Bronner G., Flesch H., Eber M., Methlin G., Abecassis J. Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas. Eur J Cancer B Oral Oncol. 1994;30B(2):113–120. doi: 10.1016/0964-1955(94)90062-0. [DOI] [PubMed] [Google Scholar]
  22. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988 Sep;96(3):440–447. [PubMed] [Google Scholar]
  23. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Furukawa M., Amenomori M., Shibagaki I., Nakao K., Ikenaga M. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994 Jun 15;54(12):3107–3110. [PubMed] [Google Scholar]
  24. Proctor A. J., Coombs L. M., Cairns J. P., Knowles M. A. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene. 1991 May;6(5):789–795. [PubMed] [Google Scholar]
  25. Schuuring E., Verhoeven E., van Tinteren H., Peterse J. L., Nunnink B., Thunnissen F. B., Devilee P., Cornelisse C. J., van de Vijver M. J., Mooi W. J. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 1992 Oct 1;52(19):5229–5234. [PubMed] [Google Scholar]
  26. Shay J. W., Wright W. E., Brasiskyte D., Van der Haegen B. A. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene. 1993 Jun;8(6):1407–1413. [PubMed] [Google Scholar]
  27. Shin K. Y., Kong G., Kim W. S., Lee T. Y., Woo Y. N., Lee J. D. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer. 1997;75(12):1788–1792. doi: 10.1038/bjc.1997.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Simpson J. F., Quan D. E., O'Malley F., Odom-Maryon T., Clarke P. E. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol. 1997 Jul;151(1):161–168. [PMC free article] [PubMed] [Google Scholar]
  29. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 1991;27(11):1372–1375. doi: 10.1016/0277-5379(91)90012-3. [DOI] [PubMed] [Google Scholar]
  30. Wang T. C., Cardiff R. D., Zukerberg L., Lees E., Arnold A., Schmidt E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994 Jun 23;369(6482):669–671. doi: 10.1038/369669a0. [DOI] [PubMed] [Google Scholar]
  31. Xu H. J., Quinlan D. C., Davidson A. G., Hu S. X., Summers C. L., Li J., Benedict W. F. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 1994 May 4;86(9):695–699. doi: 10.1093/jnci/86.9.695. [DOI] [PubMed] [Google Scholar]
  32. Zhang Y. J., Jiang W., Chen C. J., Lee C. S., Kahn S. M., Santella R. M., Weinstein I. B. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993 Oct 29;196(2):1010–1016. doi: 10.1006/bbrc.1993.2350. [DOI] [PubMed] [Google Scholar]
  33. Zukerberg L. R., Yang W. I., Arnold A., Harris N. L. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol. 1995 Jun;103(6):756–760. doi: 10.1093/ajcp/103.6.756. [DOI] [PubMed] [Google Scholar]
  34. Zukerberg L. R., Yang W. I., Gadd M., Thor A. D., Koerner F. C., Schmidt E. V., Arnold A. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol. 1995 Jun;8(5):560–567. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES